Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Deepmatter Group Plc LSE:DMTR London Ordinary Share GB00B29YYY86 ORD 0.01P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -5.0% 1.90 3,415,538 13:12:34
Bid Price Offer Price High Price Low Price Open Price
1.80 2.00 2.00 1.90 2.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 1.20 -3.36 -0.43 18
Last Trade Time Trade Type Trade Size Trade Price Currency
16:16:19 O 124,787 1.87 GBX

Deepmatter (DMTR) Latest News

More Deepmatter News
Deepmatter Investors    Deepmatter Takeover Rumours

Deepmatter (DMTR) Discussions and Chat

Deepmatter Forums and Chat

Date Time Title Posts
20/10/202020:27DeepMatter 851
19/9/202007:32Deepmatter 2

Add a New Thread

Deepmatter (DMTR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-10-20 15:16:201.87124,7872,333.52O
2020-10-20 14:37:021.80200,0003,600.00O
2020-10-20 12:52:591.8813,297249.98O
2020-10-20 12:12:131.8029,073523.31O
2020-10-20 12:11:451.8039,391709.04O
View all Deepmatter trades in real-time

Deepmatter (DMTR) Top Chat Posts

DateSubject
20/10/2020
09:20
Deepmatter Daily Update: Deepmatter Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker DMTR. The last closing price for Deepmatter was 2p.
Deepmatter Group Plc has a 4 week average price of 1.50p and a 12 week average price of 1.50p.
The 1 year high share price is 4.30p while the 1 year low share price is currently 1.50p.
There are currently 921,897,281 shares in issue and the average daily traded volume is 5,585,415 shares. The market capitalisation of Deepmatter Group Plc is £17,516,048.34.
19/10/2020
23:32
mcrudden: I guess some people struggle with big words like yourself but fail to see how 99 percent of the population could be baffled.Can be clearer than this even for people like you!!!14 April 2020 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry has signed a contract with the Cancer Research UK Beatson Institute and Cancer Research Technology (the commercialisation and development arm of Cancer Research UK) for its DigitalGlassware(TM) platform. The technology will be installed within the institute's Drug Discovery Unit to enable the accurate and reproducible sharing of its research output with its outsourced chemistry partners located in China. The use of DigitalGlassware(TM) means the Drug Discovery Unit will be able to share its cutting-edge chemistry across locations, so that work is not needlessly duplicated nor time and money wasted, and ultimately so new discoveries might be made faster.
16/10/2020
07:29
jpuff: Further Great news from this gem of a company.....DeepMatter Group PLC Strong adoption of ICSYNTHSource: UK Regulatory (RNS & others)TIDMDMTRRNS Number : 2679CDeepMatter Group PLC16 October 202016 October 2020DeepMatter Group plc("DeepMatter", the "Company" or "the Group")Strong adoption of ICSYNTHDeepMatter doubles customer numbers for its machine-learning retrosynthesis toolDeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce it has secured contracts with five new major customers over the last two months for its powerful computer aided synthesis design tool, ICSYNTH. In total, ICSYNTH customer numbers have more than doubled through the course of 2020, and the Company has achieved 100% customer renewals, adding to the Group's underlying revenue base. The new customers include some of the world's leading multi-national pharmaceutical, agrisciences, biotech and contract research organisations (CROs). Retrosynthesis is a growing area of the Life Sciences Research & Development space, providing an increasing opportunity for ICSYNTH.ICSYNTH is a powerful computer aided synthesis design tool that enables chemists to generate synthetic pathways for a target molecule, leading to better, faster and more cost-effective synthesis predictions. ICSYNTH facilitates innovation by stimulating ideas for alternative or novel synthetic routes that otherwise may not be considered by the chemist.Development work has recently been completed on a new User Interface for the tool, facilitating greater ease of use, and new algorithms have been introduced to filter out erroneous data from any data source, including proprietary data in Electronic Laboratory Notebooks, leading to improved synthesis predictions resulting in better productivity and time management.Mark Warne, Chief Executive Officer of DeepMatter commented: "We are delighted to be supplying our powerful retrosynthesis and forward planning tools to these leaders in their field, expanding our customer base not only in the Pharmaceutical industry but also within the agrisciences and CRO sectors."With machine learning and cloud technologies both powerful tools in the race to accelerated drug discovery, we see a growing opportunity for both our ICSYNTH and DigitalGlassware(TM) platforms and look to the future with confidence."For more information, please contact: DeepMatter Group plc T: 0141 548 8156 Mark Warne, Chief Executive Officer C anaccord Genuity Limited (Nominated Advisor and Broker) T: 020 7523 8000 Bobbie Hilliam / Angelos Vlatakis Alma PR T: 020 3405 0205 Caroline Forde / Harriet Jackson / Kieran deepmatter@almapr.co.uk Breheny About DeepMatter Group plcDeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware(TM), to scientists across research and process development sectors.The DigitalGlassware(TM) platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.Visit: www.deepmatter.io and follow @deepmattergroupThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDCNTMZMMGLKMGGZM(END) Dow Jones NewswiresOctober 16, 2020 02:00 ET (06:00 GMT)
23/9/2020
18:55
the stigologist: Months of ramping Several 'contracts' with Big Pharma like Astra Zeneca and Novartis Griffiths dumping Share price lower than 1 year ago despite everything else in biotech ripping higher Anybody smell a rat ? Can the resident dunces tell us why the entire market is steering clear of this p.o.s ? Surely multimillionaire high IQ Oxbridge educated investors like MrCrudDunce can't be wrong ?
14/9/2020
15:23
the stigologist: Apart from the share price ho ho
11/9/2020
15:42
the stigologist: Do you want to try telling the share price ? What did Piddler make of it ?
11/9/2020
11:57
bandflex: DMTR did not complete the acquisition of InfoChem until mid March 2019, infochem only contributed about 3.5 months revenue in H1 2019 (£222,000). H1 2020 InfoChem contributed 6 months revenue (£476,000), DMTR contributed just £60000. It seems disingenuous to claim revenue is over double H1 2019 when most of it is due to 6 months rather than 3.5 months contribution from InfoChem.
01/9/2020
13:40
yump: If you want to see hype, see SKIN, there's even the CEO tweeting every other day. People think they've made a great judgement because the share price has jumped, rather than accepting that covid has been a massive piece of luck for the PR machine. Interesting contrasts in the market. With the right hype a business with massive losses that are likely to continue for years can be rated higher than one with small losses. Especially if the business keeps taking over other businesses and issuing shares. Then the continued losses can be presented as providing a bigger opportunity in the years to come. Rinse and repeat. I guess if you can run a business and draw a salary without ever making a profit, courtesy of numpty investors, then good luck to you. I guess as with a lot of things, the bigger you can puff your chest out, the better it looks. Until you're caught out.
26/8/2020
12:22
yump: bamboo2 Your comment about gathering users spot on imo. The value here is in IP or its equivalent ie. the collected information in the cloud. As an ex-chemist, this is quite an interesting share as I have no doubt that automated and replicated syntheses of all sorts are going to increase massively. The share price is something else. The ramping, if there ever was any real ramping, was over ages ago So what can be read into the increased volatility in the chart ? Just large holdings changing hands ?
16/8/2020
22:46
bamboo2: Saw your comments on the follow feed just now. Can you explain why you think, with a NED in the boardroom, Springer will want to sell their holding? Why will the chart rollover, when a recent placing at 1.5p, had management increasing their holdings at their own expense? Springer have held their original shares for 18 months now, during which time the share price has been higher than today, so if they wanted to sell, why didn't they sell when the price was higher? Looking at the Springer turnover and profits, they don't need the cash. Far from it. What you say just doesn't add up.
06/8/2020
23:15
deutsch4: Has this piece of digital wonder ever produced a new chemical, new process, or anything new at all. If so where is the marketing. Greggs develop a new type of Pasty and their marketing department go to work. And bingo sales up profit up and share price up.........All we get here is people who already have sack loads of shares sell them off... Commenting on this conundrum is the main game of contributors here... Something tells me that the digital wizardry has not found a new pasty yet.....If it has a lot of people are selling out without being aware of anything.... For goodness sake if we cant find a new pasty then surely a new ingredient for the gravy?
Deepmatter share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DMTR
Deepmatter
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201021 03:25:49